Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Lonza Group AG    LONN   CH0013841017

LONZA GROUP AG

 (LONN)

7
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 
Sector
Healthcare
Biotechnology / Pharmaceuticals
 Biotechnology / Pharmaceuticals
  Biotechnology
Logo
Logo Lonza Group AG
Business Summary
Lonza Group is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows:
- exclusive syntheses and bio-pharmaceutical products (48.2%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.;
- fine organic and performance chemical products (43.9%): for food products, hygiene products, beauty products, water treatment and wood care products, etc.;
- bioscience products (7.5%);
- other (0.4%).
Net sales break down geographically as follows: Switzerland (13.9%), Europe (25.1%), North America (44.6%) and other (16.4%).
Surperformance© rating of Lonza Group AG
Overall rating In sector In country
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector Biotechnology
CountryTrading RatingInvestor Rating
GILEAD SCIENCES, INC.USA
AMGEN, INC.USA
BIOGEN IDEC INC.USA
CELGENE CORPORATIONUSA
CSL LIMITEDAUSTRALIA
REGENERON PHARMACEUTICALS INCUSA
VERTEX PHARMACEUTICALS INCORPORATEDUSA
LIFE TECHNOLOGIES CORP.USA
ACTELION LTDSwitzerland
ONYX PHARMACEUTICALS, INC.USA
PHARMACYCLICS, INC.USA
QIAGEN NVUSA
SEATTLE GENETICS, INC.USA
ALKERMESUSA
COVANCE INC.USA
LONZA GROUP AGSwitzerland
BEIJING SL PHARMACEUTICAL CO., LTD.CHINA
MEDIVATION INCUSA
JAZZ PHARMACEUTICALS PLCUSA
UNITED THERAPEUTICS CORPORATIONUSA
INCYTE CORPORATIONUSA
EUROFINS SCIENTIFICFrance
CELLTRION, INC.KOREA, REPUBLIC OF
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTDCHINA
-
PAREXEL INTERNATIONAL CORPORATIONUSA
Sector Biotechnology
Data source :
© 2013 Thomson Reuters
Ratings :
© 2013 Surperformance
Shareholders
- Franklin Templeton Companies LLC 9,68%
- Grupo Plafin 8,17%
- Company-owned shares 5,28%
- Marsico Capital Management 4,89%
Advertisement
Managers
- Chief Financial Officer :
    Toralf Haag
- Investor Relations :
    Alexandre Pasini
- Chief Executive Officer :
    Stefan Borgas
- Communications :
    Dominik Werner
Company contact information
38 Münchensteinerstrasse
CH-4002 Basel
Switzerland

Phone : +41 61 316 81 11
Fax : +41 61 316 91 11
Internet : http://www.lonzagroup.com
Markets and indexes
- SIX Swiss Exchange
- Main Standard
Stock Exchange Codes
- ISIN Code :  CH0013841017
- Bloomberg Code :  LONN:VX
- Reuters Code :  LONN.VX
- Datastream Code :  S:LONN
Financial data source :
© 2013 Cofisem
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.